Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STABIL-NOR semaglutide add-on study in antipsychotic-associated metabolic dysfunction
2021-004452-42Phase 3Active
- Sponsor
- Helse Bergen
- Start
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity, prediabetes and antipsychotic-induced weight gain (AIWG) comparing Semaglutide add-on with Placebo add-on (2 arms). Primary endpoint: Change in body weight from baseline to week 26. Started Oct 2022; status: active.
02
Drugs
03
Conditions
obesityprediabetesantipsychotic-induced weight gain (AIWG)
Beyond the preview
Go deeper on 2021-004452-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004452-42.